Background: Drug-induced interstitial lung disease (DIILD) occurs as a result of numerous
agents, but the risk often only becomes apparent after the marketing authorisation of such …

Since the approval of the first molecularly targeted tyrosine kinase inhibitor (TKI), imatinib, in
2001, TKIs have heralded a new era in the treatment of many cancers. Among their …

Introduction Increased post-marketing reports of interstitial lung disease in Japan have been
recognized. An understanding of its regional groundings can be important for the global …

A number of molecularly targeted anticancer drugs that efficiently inhibit receptor tyrosine
kinases, socalled receptor tyrosine kinase inhibitors (TKIs), have been developed. Although …

Drug-induced interstitial lung disease (DIILD) is a serious side effect of chemotherapy in
cancer patients with an extremely high mortality rate. In this study, to identify genetic variants …

Severe delayed drug hypersensitivity reactions comprise different clinical entities and can
involve different immune-mediated mechanisms. Common examples are severe cutaneous …

Background Drug-induced interstitial lung disease (ILD) is one of the most serious adverse
events with a high mortality rate and represents a serious clinical problem. However …

Introduction Drug-induced interstitial lung disease (DI-ILD) is increasing in incidence, due to
the use of many new drugs across a broad range of cancers and chronic inflammatory …

Aim Drug‐induced interstitial lung disease (DI‐ILD) is a serious adverse event during
chemotherapy. This study aimed to obtain real‐world data of the incidence, clinical …